Physician profile
Julie Ar Mark
NPI 1518927482
$2,643.58
in general payments reported to CMS, 2019-2025
18 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $395 · 2021: $204 · 2022: $444 · 2023: $289 · 2024: $190 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $593.74 | 2019-2025 | |
| Janssen Biotech, INC. | $514.85 | 2019-2022 | |
| Amgen INC. | $321.43 | 2020-2025 | Otezla, Enbrel, Otezla |
| Sun Pharmaceutical Industries INC. | $239.28 | 2019-2024 | |
| Celgene Corporation | $156.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $148.07 | 2019-2025 | |
| Leo Pharma INC. | $142.55 | 2019-2025 | Adbry |
| Dermavant Sciences, INC. | $126.96 | 2023 | Vtama |
| Ucb, INC. | $83.33 | 2019 | |
| Genentech USA, INC. | $81.57 | 2019-2020 | |
| Lilly USA, LLC | $45.05 | 2022-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $43.72 | 2024-2025 | Sotyktu |
| Incyte Corporation | $43.19 | 2024 | Opzelura |
| Genzyme Corporation | $37.24 | 2019-2024 | |
| Prugen, INC. Pharmaceuticals | $23.72 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $16.08 | 2024 | Visiclear |
| Galderma Laboratories, L.P. | $13.01 | 2019 | |
| Pfizer INC. | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.